[Press release – not published yet] A phase 3 trial with more than 10,000 participants showed a booster dose of the Pfizer/BioNTech vaccine had an efficacy of 95.6% against disease; there were 5 cases in the booster group and 109 cases in the non-boosted
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine Commentary: Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies say – CNN Commentaries on Twitter This will presumably mean everyone gets boosters early next year. That’s great, because they do […]
The post [Press release – not published yet] A phase 3 trial with more than 10,000 participants showed a booster dose of the Pfizer/BioNTech vaccine had an efficacy of 95.6% against disease; there were 5 cases in the booster group and 109 cases in the non-boosted group, not classified according to severity. appeared first on Links Medicus.
State of the Art Review: Diagnosis and management of bronchopulmonary dysplasia.
Diagnosis and management of bronchopulmonary dysplasia – The BMJ Commentary on Twitter This new clinical review evaluates the various clinical definitions, imaging modalities, and biomarker data that are helpful in making an early diagnosis of bronchopulmonary dysplasia (BPD), as well as the evidence on the prevention and treatment of BPD https://t.co/ITqe8WMkNl — The BMJ […]
The post State of the Art Review: Diagnosis and management of bronchopulmonary dysplasia. appeared first on Links Medicus.
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network Related: ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer Review: venous and arterial thromboembolism in patients with cancer. Systematic Review: Does testing for cancer in people with unprovoked blood […]
The post NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease. appeared first on Links Medicus.
FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK.
FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK – CNN See also: FDA OKs mixing COVID vaccines; backs Moderna, J&J boosters – Associated Press FDA OKs Moderna, J&J boosters, along with ‘mix and match’ approach – NBC News
The post FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK. appeared first on Links Medicus.
COVID-19 pneumonia: pathophysiology and management.
COVID-19 pneumonia: pathophysiology and management – European Respiratory Review
The post COVID-19 pneumonia: pathophysiology and management. appeared first on Links Medicus.
An analysis of Scotland’s mortality in 114,000 SARS-CoV2–infected people revealed that the vaccine effectiveness against death from the Delta variant was 90% for the Pfizer vaccine and 91% for AstraZeneca.
BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant – New England Journal of Medicine
The post An analysis of Scotland’s mortality in 114,000 SARS-CoV2–infected people revealed that the vaccine effectiveness against death from the Delta variant was 90% for the Pfizer vaccine and 91% for AstraZeneca. appeared first on Links Medicus.
Pfizer vaccine showed estimated effectiveness of 93% against symptomatic SARS-CoV-2 Delta variant infection in adolescents.
Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents – New England Journal of Medicine Related: CDC Study: Pfizer vaccine showed 93% effectiveness against Covid-19 hospitalization among children aged 12-18 years. Commentary on Twitter The remarkably high effectiveness (VE) of vaccination for teens vs the Delta variant in over 94,000 vaccinees and 94,000 matched […]
The post Pfizer vaccine showed estimated effectiveness of 93% against symptomatic SARS-CoV-2 Delta variant infection in adolescents. appeared first on Links Medicus.
Systematic Review: anti-interleukin-13 or anti-interleukin-4 agents may be appropriate for adults with moderate-to-severe uncontrolled asthma who have not responded to other treatments.
Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma – Cochrane Library Summary: Anti-interleukin-13 or anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for children and adults with asthma – Cochrane Library Commentary on Twitter (thread – click for more) Lead author David Evans said “Approximately five to ten […]
The post Systematic Review: anti-interleukin-13 or anti-interleukin-4 agents may be appropriate for adults with moderate-to-severe uncontrolled asthma who have not responded to other treatments. appeared first on Links Medicus.
Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes.
Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes – European Respiratory Journal
The post Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes. appeared first on Links Medicus.
Covid-19: New mutation of Delta variant under close watch in UK.
Covid-19: New mutation of Delta variant under close watch in UK – BBC
The post Covid-19: New mutation of Delta variant under close watch in UK. appeared first on Links Medicus.